Rash severity and dose in phase I dose escalation cetuximab (C225) trial
2008
14573 Background: C225 is a monoclonal antibody targeting epidermal growth factor receptor (EGFR). The FDA-approved dose is 400 mg/m2 loading with weekly maintenance at 250 mg/m2. C225 efficacy has...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
3
Citations
NaN
KQI